CITIC Group Buys Stake In China Central Pharmaceuticals
This article was originally published in PharmAsia News
Executive Summary
CITIC Asset Management, a subsidiary of CITIC Group, has injected RMB 100 million into China Central Pharmaceuticals' subsidiary Wuhan Pharmaceutical Group. China Central plans to go public the second half of 2009 on Hong Kong's main board but it does not discount listing on other stock markets. Upon China Central's listing as a full entity, CITIC Asset Management will become one of its shareholders by share swap. The investor expresses confidence in China Central's business model; the latter is forming an alliance of pharmaceutical distributors to strengthen their bargaining power in the industry. So far, 53 distribution companies covering major cities and regions across China have participated in the scheme. (Click here for more - Chinese Language)
You may also be interested in...
California Court’s Inaction On TiO2 Prop 65 First Amendment Case Breeds New Lawsuits
The Personal Care Products Council seeks to stem the rising tide of titanium dioxide Proposition 65 lawsuits, requesting that a California court prohibit the state’s Attorney General and private enforcers from filing and/or prosecuting new suits against cosmetics companies failing to warn about potential TiO2 exposure.
Kenvue Breaks Ground On New Headquarters, Appoints Chief Corporate Affairs Officer
Firm hosts groundbreaking for 290,000 square-foot global headquarters it’s having built in Summit, NJ, starting with 100,000 square-foot science and innovation and expected to open in 2025. It announced adding Russell Dyer as chief corporate affairs officer starting 13 March.
Xaira Launches With $1bn-Plus And End-To-End AI Strategy
ARCH and Foresite incubated the company and recruited Genentech R&D veteran Marc Tessier-Lavigne to keep data generation, machine learning research and drug development under one roof.